Effect of study drug IL-4RR576 polymorphism on response to dupilumab in asthma

Recruiting
99 years or below
All
1 Location

Brief description of study

The purpose of this study is to learn if the study drug (Dupixent® Dupilumab) helps to control asthma. We are particularly interested in understanding if people who have a certain genetic make-up (genotype) will respond better to this treatment. Participants will take inhaler (Dulera®mometasone/formoterol) about 2-12 weeks. Total study duration is about 18 to 22 months. Participants will come to clinic 9 times, plus extra visits if they have an asthma flare up. Participants will also have at least 1 phone visit. Compensation up to $180.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research, asthma
  • Age: 99 years or below
  • Gender: All
Updated on 04 Aug 2024. Study ID: 851324

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Please provide your preferred way of contact
Race
Select race of your choice
Ethnicity
Select ethinicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center